Advertisement

Increased dose single-agent gemcitabine in platinum–taxane resistant metastatic ovarian cancer

Abstract

Background

In platinum–taxane resistant epithelial ovarian cancer (EOC), we aimed to determine the effectiveness.

Patients and Methods

Between 2004 and 2013, patients afflicted with platinum–taxane resistant EOC and who were administered a 30-minute i.v. infusion of single-agent gemcitabine at a dose of 1,250 mg/m2 on the 1st, 8th and 15th days, every 28 days, were examined retrospectively.

Results

Twenty-six patients with platinum–taxane resistant EOC were included in the study. The overall survival (OS) was 48 months. The median survival after becoming platinum–taxane resistant was 16 months for the study population. Median time to progression (TTP) and median survival after becoming platinum–taxane resistant for patients who received second-line treatment were 3.3 months and 16 months, respectively; for patients who received third-line treatment with gemcitabine, these were 3.7 months and 19 months, respectively. Administration of gemcitabine as second- and third-line chemotherapy in platinum–taxane resistant EOC, provides similar TTP and OS outcomes (p = 0.4, p = 0.9) with a similar response and toxicity rate.

Conclusions

Second- and third-line gemcitabine at a dose of 1,250 mg/m2 on days 1, 8 and 15 every 28 days as a 30-minute i.v. infusion in platinum–taxane resistant EOC is an effective treatment option with a tolerable and manageable toxicity.

Tumori 2015; 101(1): 36 - 40

Article Type: ORIGINAL RESEARCH ARTICLE

DOI:10.5301/tj.5000209

Authors

Hilmi Kodaz, Ilhan Hacibekiroglu, Esma Turkmen, Bulent Erdogan, Cagnur Elpen, Sernaz Uzunoglu, Irfan Cicin

Article History

Disclosures

Financial support: No financial support was received for this submission.
Conflict of interest: The authors have no conflict of interest.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Department of Medical Oncology, Faculty of Medicine, Trakya University Edirne - Turkey
  • Department of Public Health Institution of Edirne, Edirne - Turkey

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.